What is Harrow's 2030?

Harrow (HROW) reported 2030 of $300M in Q1 2026.

What is the long-term trend for Harrow's 2030?

Over 2 years (2021 to 2023), Harrow's 2030 has grown at a 163.8% compound annual growth rate (CAGR), from $6.47M to $45.03M.

Harrow HROW 2030

2030 at other companies

Bausch + LombBLCO

——

ViatrisVTRS

——

Bausch Health CompaniesBHC

——

PBH

Prestige Consumer HealthcarePBH

——

OrganonOGN

——

Other financials

Income statement

See full

Revenue$44.2M-7.6%

Gross profit$27.0M-16.3%

Operating income-$22.1M-96.6%

Net income-$27.6M-55.2%

EPS (diluted)-$0.74-48.0%

Balance sheet

See full

Cash & equivalents$94.6M+41.8%

Total debt$308.6M-32.9%

Total equity$28.7M-49.1%

Total assets$419.5M+15.2%

Cash flow

See full

Operating cash flow-$9.0M-146%

CapEx$194.0K+14.1%

Free cash flow-$9.2M-147%

Valuation

See full

Market cap$1.59B+38.4%

Enterprise value$1.81B+13.8%

P/S5.9×+0.5×

Profitability

See full

Gross margin74.1%-0.4pp

Operating margin7.3%+5.2pp

Net margin-19.8%+18.0pp

FCF margin5.7%+5.0pp

Returns & leverage

See full

Return on equity-50%+17.5pp

Debt / equity10.7×+2.6×

Current ratio2.5×+1.6×

Where this comes from

Reported directly by Harrow in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour.

The official record: Harrow’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Harrow's 2030.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Harrow's 2030?: Harrow (HROW) reported 2030 of $300M in Q1 2026.
What is the long-term trend for Harrow's 2030?: Over 2 years (2021 to 2023), Harrow's 2030 has grown at a 163.8% compound annual growth rate (CAGR), from $6.47M to $45.03M.